DNLI logo

Denali Therapeutics (DNLI) Cash From Investing

Annual CFI

-$88.76 M
-$338.06 M-135.60%

December 31, 2024

Summary

Performance

1-Year Change

-135.6%

3-Year Change

-310.41%

5-Year Change

-160.09%

15-Year Change

-115.61%

DNLI Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

18.17%
DNLI annual cash flow from investing activities is higher than 18.17% of companies in Healthcare sector

High & Low

All-time High

$249.31 M
DNLI annual cash flow from investing activities is currently -135.60% below its historical high of $249.31 million

3-Year Low

-$141.39 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
DNLI previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
DNLI next annual earnings announcement has not yet been scheduled

OtherDNLIcash flowmetrics:

Annual CFF

$484.30 M
DNLI annual cash flow from financing activities is $484.30 million

Annual CFO

-$347.69 M
DNLI annual cash flow from operations is -$347.69 million

Annual FCF

-$363.61 M
DNLI annual free cash flow is -$363.61 million

Annual CAPEX

-
DNLI annual capital expenditures value is unknown

Quarterly CFI

$172.21 M
+$78.55 M+83.87%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+235%

5-Year Change

+235%

DNLI Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.89%
DNLI quarterly cash flow from investing activities is higher than 98.89% of companies in Healthcare sector

High & Low

All-time High

$172.21 M
DNLI quarterly cash flow from investing activities is currently at an all-time high

3-Year Low

-$453.19 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
DNLI previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
DNLI next earnings announcement is scheduled for May 7, 2025

OtherDNLIcash flowmetrics:

Quarterly CFF

-$4.17 M
DNLI quarterly cash flow from financing activities is -$4.17 million

Quarterly CFO

-$83.72 M
DNLI quarterly cash flow from operations is -$83.72 million

Quarterly FCF

-$88.81 M
DNLI quarterly free cash flow is -$88.81 million

Quarterly CAPEX

-
DNLI quarterly capital expenditures value is unknown

TTM CFI

-$88.76 M
+$99.16 M+52.77%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+37.22%

5-Year Change

+37.22%

DNLI TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

20.3%
DNLI TTM cash flow from investing activities is higher than 20.3% of companies in Healthcare sector

High & Low

All-time High

$249.31 M
DNLI TTM cash flow from investing activities is currently -135.60% below its historical high of $249.31 million

3-Year Low

-$187.92 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
DNLI previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
DNLI next earnings announcement is scheduled for May 7, 2025

OtherDNLIcash flowmetrics:

TTM CFF

$484.30 M
DNLI TTM cash flow from financing activities is $484.30 million

TTM CFO

-$347.69 M
DNLI TTM cash flow from operations is -$347.69 million

TTM FCF

-$363.61 M
DNLI TTM free cash flow is -$363.61 million

TTM CAPEX

-
DNLI TTM capital expenditures value is unknown

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

DNLI Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-135.6%0.0%0.0%
3 y3 years-310.4%+235.0%+37.2%
5 y5 years-160.1%+235.0%+37.2%

DNLI Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-135.6%+37.2%at high+138.0%-135.6%+52.8%
5 y5-year-135.6%+85.8%at high+138.0%-135.6%+86.0%
alltimeall time-135.6%+85.8%at high+138.0%-135.6%+86.0%

Denali Therapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Dec 2024
-$88.76 M(-135.6%)
$172.21 M(+83.9%)
-$88.76 M(-52.8%)
Sep 2024
-
$93.66 M(-5.0%)
-$187.92 M(+4.0%)
Jun 2024
-
$98.57 M(-121.8%)
-$180.66 M(+62.5%)
Mar 2024
-
-$453.19 M(-720.4%)
-$111.16 M(-144.6%)
Dec 2023
$249.31 M(-276.3%)
$73.05 M(-27.6%)
$249.31 M(+411.9%)
Sep 2023
-
$100.91 M(-40.0%)
$48.70 M(-232.4%)
Jun 2023
-
$168.07 M(-281.3%)
-$36.79 M(-68.3%)
Mar 2023
-
-$92.72 M(-27.3%)
-$116.22 M(-17.8%)
Dec 2022
-$141.39 M(+553.8%)
-$127.56 M(-927.3%)
-$141.39 M(+159.1%)
Sep 2022
-
$15.42 M(-82.6%)
-$54.58 M(-55.6%)
Jun 2022
-
$88.63 M(-175.2%)
-$123.00 M(+7.8%)
Mar 2022
-
-$117.88 M(+189.3%)
-$114.10 M(+427.6%)
Dec 2021
-$21.63 M(-96.5%)
-$40.75 M(-23.1%)
-$21.63 M(-93.8%)
Sep 2021
-
-$53.01 M(-154.3%)
-$348.22 M(-31.4%)
Jun 2021
-
$97.54 M(-483.9%)
-$507.33 M(-20.1%)
Mar 2021
-
-$25.41 M(-93.1%)
-$635.28 M(+1.9%)
Dec 2020
-$623.21 M
-$367.34 M(+73.2%)
-$623.21 M(+191.9%)
DateAnnualQuarterlyTTM
Sep 2020
-
-$212.12 M(+597.5%)
-$213.48 M(-543.5%)
Jun 2020
-
-$30.41 M(+128.1%)
$48.13 M(-66.2%)
Mar 2020
-
-$13.33 M(-131.5%)
$142.43 M(-3.6%)
Dec 2019
$147.71 M(-151.4%)
$42.38 M(-14.4%)
$147.71 M(+236.3%)
Sep 2019
-
$49.49 M(-22.5%)
$43.92 M(+12.2%)
Jun 2019
-
$63.88 M(-893.8%)
$39.16 M(+574.6%)
Mar 2019
-
-$8.05 M(-86.9%)
$5.80 M(-102.0%)
Dec 2018
-$287.42 M(+598.2%)
-$61.40 M(-237.3%)
-$287.42 M(-10.5%)
Sep 2018
-
$44.73 M(+46.5%)
-$321.17 M(-8.1%)
Jun 2018
-
$30.53 M(-110.1%)
-$349.37 M(-2.4%)
Mar 2018
-
-$301.27 M(+216.6%)
-$357.82 M(+769.2%)
Dec 2017
-$41.17 M(-81.2%)
-$95.15 M(-675.8%)
-$41.17 M(-176.3%)
Sep 2017
-
$16.53 M(-25.1%)
$53.98 M(+44.1%)
Jun 2017
-
$22.07 M(+43.5%)
$37.46 M(+143.5%)
Mar 2017
-
$15.38 M
$15.38 M
Dec 2016
-$219.00 M(+7052.3%)
-
-
Dec 2015
-$3.06 M
-
-

FAQ

  • What is Denali Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Denali Therapeutics?
  • What is Denali Therapeutics annual CFI year-on-year change?
  • What is Denali Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Denali Therapeutics?
  • What is Denali Therapeutics quarterly CFI year-on-year change?
  • What is Denali Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Denali Therapeutics?
  • What is Denali Therapeutics TTM CFI year-on-year change?

What is Denali Therapeutics annual cash flow from investing activities?

The current annual CFI of DNLI is -$88.76 M

What is the all time high annual CFI for Denali Therapeutics?

Denali Therapeutics all-time high annual cash flow from investing activities is $249.31 M

What is Denali Therapeutics annual CFI year-on-year change?

Over the past year, DNLI annual cash flow from investing activities has changed by -$338.06 M (-135.60%)

What is Denali Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of DNLI is $172.21 M

What is the all time high quarterly CFI for Denali Therapeutics?

Denali Therapeutics all-time high quarterly cash flow from investing activities is $172.21 M

What is Denali Therapeutics quarterly CFI year-on-year change?

Over the past year, DNLI quarterly cash flow from investing activities has changed by $0.00 (0.00%)

What is Denali Therapeutics TTM cash flow from investing activities?

The current TTM CFI of DNLI is -$88.76 M

What is the all time high TTM CFI for Denali Therapeutics?

Denali Therapeutics all-time high TTM cash flow from investing activities is $249.31 M

What is Denali Therapeutics TTM CFI year-on-year change?

Over the past year, DNLI TTM cash flow from investing activities has changed by $0.00 (0.00%)